SCHEMBL2012211

SCHEMBL2012211

CC1(C)CCC(C)(C)c2cc(-c3ccnc(N4CC[C@@H](N)C4)n3)ccc21

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DKK1 O94907 3/20 0.57
DYRK1A Q13627 2/20 0.48
ROCK2 O75116 2/20 0.45
RET P07949 1/20 0.42
KARS1 Q15046 1/20 0.42
PIM1 P11309 3/20 0.42
RARA P10276 1/20 0.40
RARB P10826 1/20 0.40
HRH4 Q9H3N8 2/20 0.39
HRH3 Q9Y5N1 1/20 0.39
PIK3CA P42336 2/20 0.39
PIK3CD O00329 1/20 0.39
PIK3R1 P27986 1/20 0.39
PIK3CB P42338 1/20 0.39
CYP2C19 P33261 1/20 0.38
LRRK2 Q5S007 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2012214 1.00 DKK1 (0.57) DKK1DYRK1AROCK2RETKARS1
SCHEMBL8514868 0.94 DKK1 (0.64) DKK1DYRK1AROCK2RETKARS1
Hydrochloric Acid SCHEMBL8511494 0.93 DKK1 (0.63) DKK1DYRK1AROCK2RETKARS1
SCHEMBL2016497 0.81 HRH4 (0.48) DKK1KARS1PIM1HRH4HRH3
SCHEMBL2013973 0.81 HRH4 (0.48) DKK1KARS1PIM1HRH4HRH3
SCHEMBL2013976 0.81 HRH4 (0.48) DKK1KARS1PIM1HRH4HRH3
SCHEMBL8510951 0.80 DKK1 (0.45) DKK1RETRARARARBPIK3CA
SCHEMBL8512407 0.80 ADRB1 (0.44) DKK1ROCK2RARARARBPIK3CA
SCHEMBL3652626 0.80 DKK1 (0.86) DKK1DYRK1AROCK2RETKARS1
SCHEMBL3648934 0.80 DKK1 (0.86) DKK1DYRK1AROCK2RETKARS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
EP-2513057-B1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2013-09-04 EP disclosed
EP-2513057-A1 SPHINGOSINE KINASE INHIBITORS Merck Patent GmbH (DE) 2012-10-24 EP disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
WO-2011072791-A1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE SPHK1, SPHK2, S1PR3 DKK1 2388/4885DYRK1A 314/4885ROCK2 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.